,

Lineage Acquires an Experimental Cell Therapy Program for Huntington’s Disease

Lineage closed its NeuroAirmid acquisition on November 12. The deal adds HUNT1, a neural stem cell candidate in an early Huntington’s disease trial.

A cell culture plate beside a microscope in a laboratory

Lineage Cell Therapeutics completed its acquisition of NeuroAirmid Therapeutics on November 12, adding a neural stem cell program under study for Huntington’s disease. The candidate, called HUNT1, is already in its first human trial. Lineage reported that six patients had received it as of the acquisition announcement.

Deal Check
Status Closed November 12, 2026.
At closing Approximately US$4.7 million in cash, shares and an expense fund for the sellers, plus US$1.7 million paid to settle third-party obligations.
Later payments Up to US$5 million to sellers at the first anniversary, with the SEC filing reporting up to US$5.4 million including related obligations. Up to US$48 million depends on clinical and regulatory milestones. A qualifying future transaction could trigger a separate payment.

What Lineage gained

The acquisition gives Lineage control of NeuroAirmid and access to patent rights licensed from the University of California. The amended agreement grants an exclusive licence under specified patents covering neural stem cell compositions and methods, along with non-exclusive rights to related technology. It also grants exclusive use of specified trial data for regulatory filings and rights to reference the investigational drug application supporting the trial. The university retains rights to complete the ongoing study.

NeuroAirmid had no revenue or employees, according to the SEC filing. The value to Lineage lies in the programme, licensed intellectual property and the ability to keep developing HUNT1. Lineage plans to take over further clinical development after the trial and handle future manufacturing and scale-up. The company will also assume up to US$3.1 million in trial co-funding obligations. A separate California Institute for Regenerative Medicine award of up to US$12 million supports the university’s study.

What the first human trial can show

Huntington’s disease is an inherited condition that progressively affects movement, thinking and behaviour. HUNT1 is made from pluripotent stem cells, which can develop into different kinds of tissue. The candidate consists of neural stem cells intended for implantation into the striatum, a brain region involved in movement and affected by the disease. Researchers are studying whether the transplanted cells can survive and support neural function.

The University of California, Irvine is running REGEN4HD, a Phase 1b/2a trial that plans to enrol up to 21 participants in five groups. The first phase will assess escalating doses in up to 12 people. The second phase plans to enrol up to nine more at a dose selected using first-phase results. Researchers will primarily monitor treatment-related adverse events. They will also track measures such as movement, cognition, brain imaging and a marker of nerve-cell injury.

The six people dosed by November 12 represent an early enrolment update. Clinical benefit remains unproven, and HUNT1 is investigational.

The risks that remain after closing

The programme extends Lineage’s work on donor-derived cell therapies into Huntington’s disease, with the possibility of using some of its existing manufacturing methods. A transplant into the brain brings surgical risks and questions about how the cells behave over time. Consistent manufacturing, longer safety follow-up and evidence of meaningful clinical benefit would all be needed to advance the programme. The upfront payment secures access to the asset, while much of the potential payment to sellers depends on future results.

Primary sources Lineage’s SEC Form 8-K, acquisition announcement, company clinical update, ClinicalTrials.gov registration and UC Irvine trial record.

Featured image generated with AI for The Lifespan Brief.